YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas

In a series of 404 adult soft tissue sarcomas, analyzed by array‐CGH, we have observed in approximately 10% of them a genomic amplification of either chromosome bands 11q22 or 3p12. These two amplicons likely target the YAP1 and VGLL3 genes, respectively. Both genes encode proteins that are cofactors of the TEAD family of transcription factors. Very good correlations between amplification and expression levels were observed. Welch test analyses of transcriptome data demonstrate that tumors with amplicons share a large set of upregulated and downregulated genes. Inhibition of YAP1 and VGLL3 in cell lines with these amplifications/overexpressions leads to similar phenotypes: decrease of proliferation rate, and to a lesser extent decrease of migration properties. These data, and the fact that these amplicons are observed either in dedifferentited liposarcomas or in undifferentiated pleomorphic sarcomas, suggest that these genetics events could be involved in oncogenesis and progression of soft tissue sarcomas. © 2010 Wiley‐Liss, Inc.

[1]  P. Northcott,et al.  YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. , 2009, Genes & development.

[2]  R. Sciot,et al.  Two genetic pathways, t(1;10) and amplification of 3p11–12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions , 2009, The Journal of pathology.

[3]  O. Mariani,et al.  Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas. , 2009, Cancer research.

[4]  L. Donehower,et al.  MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. , 2009, Cancer research.

[5]  Y. Yatabe,et al.  YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. , 2008, Carcinogenesis.

[6]  R. Jaenisch,et al.  YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells , 2007, Current Biology.

[7]  Li Li,et al.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.

[8]  G. Feldmann,et al.  Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.

[9]  O. Mariani,et al.  JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. , 2007, Cancer cell.

[10]  Flavio Giordano,et al.  Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Wigler,et al.  Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach , 2006, Cell.

[12]  Olivier Delattre,et al.  Two types of chromosome 1p losses with opposite significance in gliomas , 2005, Annals of neurology.

[13]  Cathie Garnis,et al.  Multiple microalterations detected at high frequency in oral cancer. , 2005, Cancer research.

[14]  J. Fridlyand,et al.  Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma , 2005, Oncogene.

[15]  Robert Tibshirani,et al.  Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. , 2005, Neoplasia.

[16]  R. Gentleman,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[17]  O. Mariani,et al.  ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14–q15 and 6q23 amplifications , 2004, Genes, chromosomes & cancer.

[18]  J. Coindre,et al.  Evaluation of MDM2 and CDK4 amplification by real‐time PCR on paraffin wax‐embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well‐differentiated liposarcomas , 2004, The Journal of pathology.

[19]  Wei-Guo Zhu,et al.  A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. , 2003, Human molecular genetics.

[20]  Masahiko Miura,et al.  Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. , 2002, Cancer research.

[21]  F. Speleman,et al.  Quantification of MYCN, DDX1, and NAG Gene Copy Number in Neuroblastoma Using a Real-Time Quantitative PCR Assay , 2002, Modern Pathology.

[22]  F. Collin,et al.  Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas , 2001, Cancer.

[23]  M. DePamphilis,et al.  TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. , 2001, Genes & development.

[24]  A. Nicolas,et al.  Leiomyosarcomas and Most Malignant Fibrous Histiocytomas Share Very Similar Comparative Genomic Hybridization Imbalances: An Analysis of a Series of 27 Leiomyosarcomas , 2001, Laboratory Investigation.

[25]  F. Chibon,et al.  The RB1 gene is the target of chromosome 13 deletions in malignant fibrous histiocytoma. , 2000, Cancer research.

[26]  P. Vaudin,et al.  TONDU (TDU), a novel human protein related to the product of vestigial (vg) gene of Drosophila melanogaster interacts with vertebrate TEF factors and substitutes for Vg function in wing formation. , 1999, Development.

[27]  R. Weichselbaum,et al.  Some retinoblastomas, osteosarcomas, and soft tissue sarcomas may share a common etiology. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Coindre,et al.  Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system , 1984, International journal of cancer.

[29]  Cdm Fletcher,et al.  World Health Organization Classification of Tumours , 2002 .

[30]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[31]  F. Collin,et al.  Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.